Skip to main content

Table 5 Medication used in the CAA population before and after CAA diagnosis

From: Prescribing patterns of coronary artery aneurysm in Taiwan

  Before index date After index date
1 year 3 month 6 month 1 year
N = 811 N (%) N (%) N (%) N (%)
Antithrombotic agent 555 (68.4) 680 (83.8) 700 (86.3) 722 (89.0)
 Aspirin 477 (58.8) 568 (70.0) 587 (72.4) 615 (75.8)
 Clopidogrel 163 (20.1) 329 (40.6) 338 (41.7) 351 (43.3)
 Dipyridamole 34 (4.2) 12 (1.5) 22 (2.7) 31 (3.8)
 Cilostazol 13 (1.6) 18 (2.2) 20 (2.5) 29 (3.6)
 Ticlopidine 12 (1.5) 10 (1.2) 16 (2.0) 20 (2.5)
 Warfarin 33 (4.1) 76 (9.4) 97 (12.0) 109 (13.4)
Antihypertensive agent 599 (73.9) 613 (75.6) 675 (83.2) 703 (86.7)
 ACEI 161 (19.9) 144 (17.8) 163 (20.1) 181 (22.3)
 ARBs 234 (28.9) 229 (28.2) 261 (32.2) 300 (37.0)
 CCBs 348 (42.9) 283 (34.9) 324 (40.0) 371 (45.7)
 β-blockers 289 (35.6) 197 (24.3) 314 (38.7) 392 (48.3)
 Diuretics 171 (21.1) 181 (22.3) 210 (25.9) 237 (29.2)
 α-blockers 116 (14.3) 76 (9.4) 105 (12.9) 129 (15.9)
Antidyslipidemic agents 291 (35.9) 321 (39.6) 370 (45.6) 410 (50.6)
 Statins 257 (31.7) 300 (37.0) 349 (43.0) 386 (47.6)
 Fibrates 53 (6.5) 24 (3.0) 31 (3.8) 50 (6.2)
 Others 11 (1.4) 13 (1.6) 14 (1.7) 18 (2.2)
Antidiabetic agents 177 (21.8) 144 (17.8) 170 (21.0) 187 (23.1)
 Metformin 114 (14.1) 79 (9.7) 96 (11.8) 117 (14.4)
 Sulfonylureas 132 (16.3) 98 (12.1) 107 (13.2) 117 (14.4)
 Thiazolidinedione (TZD) 43 (5.3) 23 (2.8) 31 (3.8) 33 (4.1)
 DDP-4 inhibitors 10 (1.2) 10 (1.2) 16 (2.0) 23 (2.8)
 Others 45 (5.5) 28 (3.5) 38 (4.7) 49 (6.0)
Nitrates 265 (32.7) 290 (35.8) 350 (43.2) 388 (47.8)
 Nitroglycerin 43 (5.3) 11 (1.4) 27 (3.3) 74 (9.1)
 Isosorbide dinitrate 57 (7.0) 58 (7.2) 75 (9.2) 86 (10.6)
 Isosorbide mononitrate 184 (22.7) 216 (26.6) 246 (30.3) 267 (32.9)
 Nicorandil 41 (5.1) 24 (3.0) 44 (5.4) 69 (8.5)
  1. ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, TZD thiazolidinedione, DDP-4 inhibitor dipeptidyl peptidase-4 inhibitor